A Comparison of the Efficacy of Immunomodulatory-Containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug –containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens.
ConclusionLow-dose TSEBT with adjuvant therapy results in adequate symptom palliation, comparable to standard-dose TSEBT. Low-dose TSEBT should be considered a standard treatment option in this population.
ConclusionFrailty status assessment resulted in the identification of a group of unfit patients who had adequate tolerance to adjusted chemotherapy (R-choP) with good results.
ConclusionGiven the low rates of CNS relapse in this series, it is difficult to discern the impact of current risk stratification combined with intrathecal prophylaxis on outcomes. Our observation that many high-risk patients did not receive prophylaxis while many low-risk patients received prophylaxis emphasizes the need for a standardized approach.
We report the results of adjusted chemotherapy according to frailty status as per the Cardiovascular Health Study (CHS) criteria. This tool is useful in decision-making because it identifies groups with different clinical behaviors.
This single-center study of 112 DLBCL patients evaluated indices predicting CNS relapse and outcomes related to the use of intrathecal prophylaxis of which the benefit is not well described. No difference was found in the rate of CNS relapse regardless of baseline risk or administration of intrathecal prophylaxis due to a low relapse rate and physician practices varied widely.
Low-dose total skin electron therapy (TSEBT) for Mycosis Fungoides has recently shown promising results when compared to standard-dose TSEBT. This retrospective study found no difference in overall survival or progression free survival between two groups of patients treated with either regimen. The use of low-dose TSEBT with adjuvant therapy may provide equivalent clinical benefit with lower rates of toxicity.
ConclusionsOur data provide pre-clinical information that can be incorporated into future early-phase clinical trials for the assessment of carfilzomib as a treatment for children with refractory hematological malignancies.
AbstractThe relationship between psoriasis and cancer has not yet been established. The aim of this study was to evaluate the association of psoriasis with certain cancers using national statistics. All patients with psoriasis (n = 892 089; 51.7% male) and age‐ and sex‐matched control subjects (n = 4 460 445) at a 5:1 ratio were enrolled using data from the National Health Insurance Service between 2007 and 2014 in Korea. In psoriatic subjects, overall cancer risk was higher than for subjects without psoriasis after adjusting for income level, diabetes, hypertension, dyslipidemia and ...
Publication date: Available online 13 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yutong Wang, Li Bao, Bin Chu, Shan Gao, Minqiu Lu, Lei Shi, Lina Fu, Lijuan Fang, Qiuqing Xiang
Publication date: Available online 13 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prasanth Ganesan, Manikandan Dhanushkodi, Trivadi S. Ganesan, Venkatraman Radhakrishnan, Krishnarathinam Kannan, Shirley Sundersingh, Tenali Gnana Sagar